Evidence map›Paper›PMID 38203614›Full record

ReviewInternational journal of molecular sciences2023

Towards Understanding Neurodegenerative Diseases: Insights from

Yingjie Wu, Yining Chen, Xiaochun Yu, Minxing Zhang, Zhaoyu Li

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Frontiers in aging neuroscience · 2026
    Review
  3. Unraveling Molecular Targets for Neurodegenerative Diseases ThroughInternational journal of molecular sciences · 2025
    Review
  4. Modelling phenotypes, variants and pathomechanisms of syndromic diseases in different systems.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2024
    Article
  5. Olfactory dysfunction as an early pathogenic indicator inFrontiers in aging neuroscience · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yingjie WuQueensland Brain Institute, The University of Queensland, Brisbane, QLD 4072, Australia.
Yining ChenQueensland Brain Institute, The University of Queensland, Brisbane, QLD 4072, Australia.
Xiaochun YuQueensland Brain Institute, The University of Queensland, Brisbane, QLD 4072, Australia.
Minxing ZhangQueensland Brain Institute, The University of Queensland, Brisbane, QLD 4072, Australia.
Zhaoyu LiQueensland Brain Institute, The University of Queensland, Brisbane, QLD 4072, Australia.

Funding

National Health and Medical Research Council 2002472
6 · The paper itself

Abstract

The elevated occurrence of debilitating neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), Alzheimer's disease (AD), Parkinson's disease (PD) and Machado-Joseph disease (MJD), demands urgent disease-modifying therapeutics. Owing to the evolutionarily conserved molecular signalling pathways with mammalian species and facile genetic manipulation, the nematode

Indexed as

Alzheimer DiseaseHuntington DiseaseNeurodegenerative DiseasesParkinson DiseaseAnimalsCaenorhabditis elegansMammalsamyloid β1-42C9ORF72C. elegansFUSgain-of-toxicitypolyQSOD1tauTDP-43α-synuclein

Identifiers

PMID38203614
PMCPMC10778690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.